Irving-based healthcare services giant McKesson Corp. has launched InspiroGene by McKesson, a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs).

“Over the last few years, McKesson has leveraged its extensive supply chain expertise and customer-centric approach to build our cell and gene therapy business, with a focus on guiding innovative medicines from clinical development to commercial success,” Joe DePinto, head of Cell, Gene, and Advanced Therapies at McKesson, said in a statement. “Today’s launch of InspiroGene by McKesson is an exciting step forward in our evolution, with a new brand that reflects the work we are doing to transform care for patients and advance health outcomes for all.”

The company said that with a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape, ensuring patients can access the life-changing treatments they need.

McKesson, ranked ninth on the Fortune 500 list, said that InspiroGene brings what it called “unparalleled experience” in every stage of the CGT life cycle.

Addressing ‘complex challenges’

Here’s how InspiroGene said it aims to address the complex challenges of bringing CGTs to market, per McKesson:

• Third-party logistics (3PL) programs that meet the unique demands of CGT manufacturers, with financial management solutions, logistics, and cutting-edge data analytics to provide seamless operations for CGTs.
• Specialty distribution services that leverage McKesson’s extensive supply chain network, offering high-touch logistics and advanced data analytics to ensure CGTs reach patients efficiently and effectively.
• Biologics specialty pharmacy solutions dedicated to CGTs, including precision dispensing to expedite time to treatment, and patient management services to efficiently address the unique needs of patients based on therapy type.
• CGT dedicated patient hub that provides tailored access and support services for patients, as well as operational case management for providers, patients, and caregivers.

In addition, the company said InspiroGene offers a tech platform that provides visibility within the CGT value chain by integrating product data and financial flows to empower CGT manufacturers, providers, and patients to deliver exceptional care and achieve transformative clinical outcomes.

McKesson Corp. partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.